Effects of recombinant bovine somatotropin on luteinizing hormone and ovarian function in lactating dairy cows.
Thirty-two lactating Holstein cows were assigned to 1 of 4 groups in a randomized block design using a 2 X 2 factorial arrangement of treatments. Recombinant bovine growth hormone (rbSt; 25 mg/day) or placebo was administered beginning at Day 35 or 70 postpartum. All cows began treatment approximately 3 days post-estrus. Blood samples were collected at least once daily for a 70-day period to determine the concentration of progesterone and the duration of the luteal and follicular phases. During estrous cycles 1 and 3, frequent blood samples were taken (every 10 min for 8 h) 24 and 60 h after the onset of luteal regression. These samples were assayed for luteinizing hormone (LH), and samples coincident with the second LH pulse detected were assayed for estradiol. Ultrasonography was used to determine the size of the largest ovarian follicle from Day 17 until ovulation in estrous cycles 1 and 3. Luteal life span, length of the follicular phase, and diameter of the largest follicle were not affected by treatment with rbSt. Administration of rbSt increased the concentration of progesterone in plasma during the first two luteal phases (p less than 0.01). Progesterone was elevated during the mid-luteal phase of cycle 3 in rbSt-treated cows that began treatment about Day 35 postpartum but not in cows that began treatment on Day 70 postpartum (Treatment X Stage X Day, p less than 0.01). During the first follicular phase studied, LH pulse frequency was higher (p = 0.06) in rbSt-treated cows than in cows receiving the placebo.(ABSTRACT TRUNCATED AT 250 WORDS)
Schemm
S R
SR
Department of Dairy and Animal Science, Pennsylvania State University, University Park 16802.
Deaver
D R
DR
Griel
L C
LC
Muller
L D
LD
D000818:Animals; D002417:Cattle; D004971:Estrus / Q000187:drug effects*; D005260:Female; D013006:Growth Hormone / Q000494:pharmacology*; D007774:Lactation; D007986:Luteinizing Hormone / Q000097:blood / Q000378:metabolism / Q000494:pharmacology*; D006080:Ovarian Follicle / Q000187:drug effects / Q000502:physiology; D010053:Ovary / Q000187:drug effects / Q000502:physiology*; D011374:Progesterone / Q000097:blood; D011994:Recombinant Proteins / Q000494:pharmacology; D012016:Reference Values
D011994:Recombinant Proteins; D011374:Progesterone; D007986:Luteinizing Hormone; D013006:Growth Hormone